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Abstract
Background: Transplantation of genetically modified bone marrow concentrates is an attractive approach to conveniently
activate the chondrogenic differentiation processes as a means to improve the intrinsic repair capacities of damaged
articular cartilage.
Methods: Human bone marrow aspirates were co-transduced with recombinant adeno-associated virus (rAAV) vectors
to overexpress the pleiotropic transformation growth factor beta (TGF-β) and the cartilage-specific transcription factor
sox9 as a means to enhance the chondroreparative processes in conditions of specific lineage differentiation.
Results: Successful TGF-β/sox9 combined gene transfer and overexpression via rAAV was achieved in chondrogenically
induced human bone marrow aspirates for up to 21 days, the longest time point evaluated, leading to increased
proliferation, matrix synthesis, and chondrogenic differentiation relative to control treatments (reporter lacZ treatment,
absence of vector application) especially when co-applying the candidate vectors at the highest vector doses tested.
Optimal co-administration of TGF-β with sox9 also advantageously reduced hypertrophic differentiation in the aspirates.
Conclusions: These findings report the possibility of directly modifying bone marrow aspirates by combined therapeutic
gene transfer as a potent and convenient future approach to improve the repair of articular cartilage lesions.
Keywords: Human bone marrow aspirates, Recombinant adeno-associated virus, Combined gene transfer, Transforming
growth factor beta, SOX9, Chondrogenesis
Background
Articular cartilage over the surface of epiphysis of bone
is a highly specialized connective tissue formed by chon-
drocytes, enabling almost smooth, frictionless movement
between the articulating surfaces of diarthrodial joints.
Due to its intrinsic limited potential for self-healing,
damaged articular cartilage is not capable of restoring its
original structure and functions and often degenerates
towards osteoarthritis. Currently available therapeutic
options in the clinics have increasingly focused on cell-
based approaches including bone marrow stimulation
techniques (microfracture, pridie drilling, abrasion) that
promote the penetration of chondroregenerative cells
from the subchondral bone marrow in sites of cartilage
lesions (Madry et al. 2010). Yet, such procedures do not
allow to reproduce the original cartilage, allowing only
for the production of a fibrocartilaginous repair tissue
made of type-I collagen and of poor mechanical quality,
but not of the native, highly organized hyaline cartilage
(proteoglycans, type-II collagen) capable of supporting
joint loading and motion (Breinan et al. 2000; Frisbie et
al. 2003; Madry et al. 2010; Orth et al. 2014).
While administration of human bone marrow-derived
mesenchymal stem cells (hMSCs) has been already
attempted in patients to activate the regenerative
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processes in focal cartilaginous lesions (Haleem et al.
2010; Kuroda et al. 2007; Nejadnik et al. 2010; Orth et
al. 2014; Skowronski and Rutka 2013; Wakitani et al.
2004; Wakitani et al. 2007), the necessity of applying
multiple steps to harvest the cells and propagate them
over time in vitro has weakened its widespread clinical
application. Application of bone marrow concentrates
containing chondrogenically competent MSCs among
other cell populations (hematopoietic cells, fibroblast-
like cells) in a natural biochemical (growth factors)
microenvironment instead may provide less demanding
approaches for the goal of therapeutic transplantation in
cartilage defects (Gigante et al. 2012; Kim et al. 2014;
Slynarski et al. 2006) as also performed to treat femoral
head necrosis and nonunion bone fractures (Hauzeur
and Gangji 2010; Kon et al. 2012). Still, even though
encouraging results have been obtained when implanting
such samples in preclinical models and in patients, the
current outcomes have not been consistently associated
with the formation of a functional, hyaline-like repair tis-
sue that fully and stably integrates with the surrounding,
intact cartilage (Gigante et al. 2012; Ivkovic et al. 2010;
Kim et al. 2014; Pascher et al. 2004; Slynarski et al. 2006).
In this regard, geneticmodificationof bonemarrowcon-
centratesby transferof sequencescoding forchondrogenic
and/or chondroreparative factors prior to implantation in
sites of cartilage injury might be a powerful tool to over-
come suchcritical issues (Frisch et al. 2015; Johnstone et al.
2013). Various therapeutic sequences have been tested to
achieve this goal, including the cartilage oligomericmatrix
protein (COMP), bone morphogenetic proteins (BMPs),
transforming growth factor beta (TGF-β), insulin-like
growth factor I (IGF-I), basic fibroblast growth factor
(FGF-2), the sex-determining region Y-type high-mobility
groupbox (SOX) familyof transcription factors, zinc finger
protein 145 (ZNF145), Indian hedgehog (Ihh),Wnt11, and
small interfering RNA (siRNA) against p53 and runt-
related transcription factor 2 (Runx2) (Babister et al. 2008;
Cucchiarini et al. 2009; Cucchiarini et al. 2011; Frisch et al.
2014;Haleem-Smith et al. 2012;Huang et al. 2010; Ikeda et
al. 2004; Jeon et al. 2012; Kim and Im 2011; Lee et al. 2011;
Liu et al. 2011; Liu et al. 2013; Liu et al. 2014; Liu et al. 2015;
Neumann et al. 2013; Pagnotto et al. 2007; Steinert et al.
2009; Steinert et al. 2012; Tao et al. 2016; Venkatesan et al.
2012). Interestingly, previous reports fromdiverse groups,
among which ours, demonstrated that multiple thera-
peuticgenetransfermightbenecessarytopromoteoptimal
reparative activities in various cells of the musculoskeletal
system (articular chondrocytes, MSCs) (Cucchiarini et al.
2009; Ikeda et al. 2004;Kimand Im2011; Liu et al. 2013;Liu
etal.2015;Steinertetal.2009;Taoetal.2016).
In light of our work showing the therapeutic benefits of
overexpressing TGF-β simultaneously with sox9 in iso-
lated human MSCs (Tao et al. 2016) and independently in
human bone marrow aspirates (Frisch et al. 2016;
Rey-Rico et al. 2015) without any interference of
independent vectors in dual versus single gene trans-
fer, we tested here the possibility of co-delivering
these two highly chondrogenic factors to further en-
hance the repair processes in primary human bone
marrow aspirates. We specifically focused on gene
transfer using the clinically adapted recombinant
adeno-associated virus (rAAV) vectors that can trans-
duce MSCs at very high efficiencies (up to 100%) and
over extended periods of time (at least 3 weeks) with-
out altering their differentiation potential (Cucchiarini
et al. 2009; Cucchiarini et al. 2011; Frisch et al. 2014;
Lee et al. 2011; Pagnotto et al. 2007; Tao et al. 2016;
Venkatesan et al. 2012). Of further note, transduction
via rAAV does not raise viral interference, allowing
for concomitant administration of independent vec-
tors in their targets (Cucchiarini et al. 2009).
For the first time to our best knowledge, we provide
evidence that successful, prolonged co-overexpression of
TGF-β and sox9 using this vector class synergically
enhances the levels of proliferation, biosynthesis, and
chondrogenesis in human bone marrow concentrates
relative to control conditions (reporter lacZ treatment,
absence of vector application) while delaying undesirable
hypertrophic and osteogenic differentiation. These
observations support the concept of modifying bone
marrow aspirates by multiple rAAV vectors as a promis-
ing approach for future implantation procedures in
articular cartilage defects in vivo.
Methods
Chemicals and reagents
All reagents were purchased at Sigma (Munich,
Germany) unless otherwise indicated. The dimethyl-
methylene blue dye was from Serva (Heidelberg,
Germany). Recombinant TGF-β3 was from Peprotech
(Hamburg, Germany). The antibodies used for
immunohistochemical analyses were as follows: the anti-
β-galactosidase (β-gal) (GAL-13) and anti-type-X colla-
gen (COL-10) antibodies from Sigma, the anti-TGF-β
(V), anti-SOX9 (C-20), and anti-FLAG tag (BioM2) anti-
bodies from Santa Cruz Biotechnology (Heidelberg,
Germany), the anti-type-I collagen (COL-1) antibody
from Abcam (Cambridge, UK), and the anti-type-II col-
lagen (II-II6B3, NIH Hybridoma Bank, University of
Iowa, Ames, USA) antibody from Acris (Hiddenhausen,
Germany). Biotinylated secondary antibodies and the
ABC reagent were purchased at Vector Laboratories
(Alexis Deutschland GmbH, Grünberg, Germany). The
TGF-β enzyme-linked immunosorbent assay (active
hTGF-β1 Quantikine ELISA) was from R&D Systems
(Wiesbaden, Germany).
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Human bone marrow aspirates
Human bone marrow aspirates (~15 ml; 1.4 ± 0.4 × 109
cells/ml) were obtained from the distal femurs of osteo-
arthritic patients undergoing total knee arthroplasty (n
= 8, age 69 ± 11 years) (Frisch et al. 2016; Rey-Rico et al.
2015). All patients provided informed consent before
inclusion in the study and all procedures were in accord-
ance with the Helsinki Declaration. The study was ap-
proved by the Ethics Committee of the Saarland
Physicians Council (Application 06/08).
Plasmids and rAAV vectors
The parental AAV-2 genomic clone pSSV9 was used to
create all constructs applied in this study (Samulski et al.
1987; Samulski et al. 1989). rAAV-lacZ carries the lacZ
gene for E. coli β-galactosidase under the control of the
cytomegalovirus immediate-early (CMV-IE) promoter.
rAAV-hTGF-β carries a 1.2-kb human transforming
growth factor beta 1 (hTGF-β1, active form) cDNA
fragment and rAAV-FLAG-hsox9 a 1.7-kb FLAG-
tagged human sox9 (hsox9) cDNA, both cloned in
rAAV-lacZ in place of lacZ (Cucchiarini et al. 2009;
Cucchiarini et al. 2011; Frisch et al. 2014; Frisch et al.
2016; Rey-Rico et al. 2015; Tao et al. 2016; Venkatesan
et al. 2012). rAAV were packaged as conventional (not
self-complementary) vectors using the 293 adenovirus-
transformed embryonic kidney cell line. Adenovirus 5
was used to provide helper functions in combination
with the pAd8 helper plasmid as previously described
(Cucchiarini et al. 2009; Cucchiarini et al. 2011; Frisch
et al. 2014; Frisch et al. 2016; Rey-Rico et al. 2015; Tao
et al. 2016; Venkatesan et al. 2012). The vectors were
purified, dialyzed, and titrated by real-time PCR
(Cucchiarini et al. 2009; Cucchiarini et al. 2011; Frisch
et al. 2014; Frisch et al. 2016; Rey-Rico et al. 2015; Tao
et al. 2016; Venkatesan et al. 2012), averaging 1010
transgene copies/ml (ratio virus particles to functional
vectors = 500/1).
rAAV-mediated gene transfer
Aspirates were aliquoted in standard tissue culture plas-
tic 96-well plates (100 μl of aspirate/well) and immedi-
ately transduced with the rAAV vectors (rAAV-lacZ: 20
or 40 μl) or co-transduced (rAAV-hTGF-β/rAAV-FLAG-
hsox9: 10 or 20 μl each vector) with each aliquot (8 ×
105 functional recombinant viral particles, MOI = 10 ± 3)
(Frisch et al. 2016; Rey-Rico et al. 2015), while aspirates
were added only 40 μl DMEM medium as the negative
control group. A volume of 60 μl of chondrogenic
medium (4.5 g/l DMEM high glucose, 100 U/ml penicil-
lin and 100 μl/ml streptomycin, 6.25 μg/ml insulin,
6.25 μg/ml transferrin, 6.25 μg/ml selenious acid,
5.35 μg/ml linoleic acid, 1.25 μg/ml BSA, 1 mM sodium
pyruvate, 37.5 μg/ml ascorbate 2-phosphate, 10−7 M
dexamethasone, 10 ng/ml TGF-β3) was then added per
aspirate with 250 μl of the abovementioned medium
change performed once per week for MSC chondrogene-
sis for up to 21 days (Barry et al. 2001; Frisch et al. 2016;
Johnstone et al. 1998; Rey-Rico et al. 2015; Yoo et al.
1998). To avoid attachment on the bottom of the plates,
the aspirates were carefully mixed after each medium
change. For osteogenic and adipogenic differentiation,
the aspirates were transduced using similar rAAV-
mediated gene transfer conditions as those described
above and then induced either toward osteogenic differ-
entiation using the StemPro Osteogenesis Differentiation
kit or adipogenic differentiation using the StemPro
Adipogenesis Differentiation kit (Life Technologies
GmbH, Darmstadt, Germany) (Frisch et al. 2016).
Detection of transgene expression
To assess TGF-β secretion, 30 μl of culture supernatant
were collected at the denoted time points 24 h after
medium change and centrifuged to remove debris and
TGF-β production was measured by ELISA as previously
described (Frisch et al. 2016). Quantitative measure-
ments were performed on a GENios spectrophotometer/
fluorometer (Tecan, Crailsheim, Germany). Moreover,
after 21 days, the aspirates were collected by centrifuga-
tion at 1.500 rpm/min for 5 min to form pellet and
subsequently fixed in 4% formalin, dehydrated in graded
alcohols, embedded in paraffin, and sectioned (3 μm).
Transgene expression (lacZ, TGF-β, sox9, FLAG) was
also assessed by immunohistochemical analyses using
specific primary antibodies, biotinylated secondary anti-
bodies, and the ABC method with diaminobenzidine as
the chromogen (Cucchiarini et al. 2009; Cucchiarini et
al. 2011; Frisch et al. 2014; Frisch et al. 2016; Rey-Rico
et al. 2015; Tao et al. 2016; Venkatesan et al. 2012). To
control for secondary immunoglobulins, the samples
were processed with omission of the primary antibody.
Samples were examined under light microscopy (Olym-
pus BX 45) (Olympus, Hamburg, Germany).
Histological, immunocytochemical, and
immunohistochemical analyses
Aspirates were collected and centrifuged to form pellet,
fixed in 4% formalin, dehydrated in graded alcohols, em-
bedded in paraffin, and sectioned (3 μm). Sections were
stained with hematoxylin eosin (H&E) for cellularity,
toluidine blue for matrix proteoglycans, and alizarin red
for matrix mineralization (Cucchiarini et al. 2009;
Cucchiarini et al. 2011; Frisch et al. 2014; Frisch et al.
2016; Rey-Rico et al. 2015; Tao et al. 2016; Venkatesan
et al. 2012). Immunohistochemical analyses were per-
formed to monitor the expression of type-II, −I, and -X
collagen using specific primary antibodies, biotinylated
secondary antibodies, and the ABC method with
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diaminobenzidine as the chromogen (Cucchiarini et al.
2009; Cucchiarini et al. 2011; Frisch et al. 2014; Frisch et
al. 2016; Rey-Rico et al. 2015; Tao et al. 2016;
Venkatesan et al. 2012). To control for secondary immu-
noglobulins, sections were processed with omission of
the primary antibody. Samples were examined under
light microscopy (Olympus BX 45).
Morphometric analyses
The levels of cells expressing the transgene (% of β-gal+
cells), the cell densities on H&E-stained sections, the
densities of toluidine blue and alizarin red staining and
those of type-II, −I, and -X collagen, TGF-β, and SOX9
immunostaining were monitored at three random
standardized sites or with 10 serial histological and im-
munohistochemical sections for each parameter, test and
replicate condition using the SIS analySIS program
(Olympus), Adobe Photoshop (Adobe Systems,
Unterschleissheim, Germany), and Scion Image (Scion
Corporation, Frederick, MD, USA) (Cucchiarini et al.
2009; Cucchiarini et al. 2011; Frisch et al. 2014; Frisch et
al. 2016; Rey-Rico et al. 2015; Tao et al. 2016; Venkate-
san et al. 2012). To evaluate β-gal expression, only cells
strongly stained versus (faint) background DAB signal,
i.e. in the absence of primary antibody, were considered
as β-gal+. Regarding the measurements of the cell dens-
ities, H&E-stained sections from either lacZ-, TGF-β-,
and sox9-treated aspirates were analyzed by counting
cells per standardized area using a similar magnification
(x40) for all types of samples in order to allow for strict
comparison. To monitor the staining intensities, x20 im-
ages were first converted to inverted grayscale mode.
Background DAB signal was adapted for comparable
range of each type of immunostaining prior to evalua-
tions. The total areas (mm2) covered with cells were
next measured to identify the average gray value of the
defined area. Data are given as mean intensity of staining
or immunostaining per mm2 of total cell area.
Biochemical assays
The aspirates were collected and digested with papain as
previously described (Frisch et al. 2016). A fluorimetric
assay using Hoechst 22358 was applied to determine the
DNA contents and the proteoglycans were measured by
binding to dimethylmethylene blue dye (Cucchiarini
et al. 2009; Cucchiarini et al. 2011; Frisch et al. 2014;
Frisch et al. 2016; Rey-Rico et al. 2015; Tao et al. 2016;
Venkatesan et al. 2012). Total cellular proteins were
monitored via protein assay (Pierce Thermo Scientific,
Fisher Scientific, Schwerte, Germany) and subsequently
used to normalize the biochemical data. All measure-
ments were performed on a GENios spectrophotometer/
fluorometer (Tecan).
Real-time RT-PCR analyses
Total cellular RNA was extracted from all the aspirates at
the denoted time points using TRIzol reagent (Ambion® Life
Technologies) and the RNeasy Protect Mini Kit with an
on-column RNase-free DNase treatment (Qiagen, Hilden,
Germany) and RNA elution in 30 μl RNase-free water. 8 μl
of eluate were applied to perform reverse transcription by
using the 1st Strand cDNA Synthesis kit for RT-PCR (AMV)
(Roche Applied Science). Real-time PCR was carried out to
amplify 2 μl of the cDNA product by using the Brilliant
SYBR Green QPCR Master Mix (Stratagene, Agilent
Technologies, Waldbronn, Germany) on an Mx3000P QPCR
operator system (Stratagene) as follows: (95 °C, 10 min),
amplification by 55 cycles (denaturation at 95 °C, 30 s;
annealing at 55 °C, 1 min; extension at 72 °C, 30 s),
denaturation (95 °C, 1 min), and final incubation (55 °C,
30 s) (Frisch et al. 2016). All primers were purchased at
Invitrogen (Darmstadt, Germany): SOX9 (chondrogenic
marker) (forward 5′-ACACACAGCTCACTCGACCTTG-
3′; reverse 5′-GGGAATTCTGGTTGGTCCTCT-3′), aggre-
can (ACAN) (chondrogenic marker) (forward 5′-GAGATG
GAGGGTGAGGTC-3′; reverse 5′-ACGCTGCCTCGGGC
TTC-3′), type-II collagen (COL2A1) (chondrogenic marker)
(forward 5′-GGACTTTTCTCCCCTCTCT-3′; reverse
5′-GACCCGAAGGTCTTACAGGA-3′), type-I collagen
(COL1A1) (osteogenic marker) (forward 5′-ACGTCCTGG
TGAAGTTGGTC-3′; reverse 5′-ACCAGGGAAGCCTCT
CTCTC-3′), type-X collagen (COL10A1) (marker of
hypertrophy) (forward 5′-CCCTCTTGTTAGTGCCAACC-
3′; reverse 5′-AGATTCCAGTCCTTGGGTCA-3′), and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(housekeeping gene and internal control) (forward 5′-
GAAGGTGAAGGTCGGAGTC-3′; reverse 5′-GAAGATG
GTGATGGGATTTC-3′) (all 150 nM final concentration)
(Frisch et al. 2016). Water and non-reverse-
transcribed mRNA were used as control conditions.
To confirm the specificity of the products, melting
curve analysis and agarose gel electrophoresis were
performed. The threshold cycle (Ct) value for each
amplified sample and each gene of interest was mea-
sured by using the MxPro QPCR software (Strata-
gene), and values were normalized to GAPDH
expression by using the 2-ΔΔCt method (Frisch et al.
2016).
Statistical analyses
All conditions were performed in triplicates in three
independent experiments for each patient and all pa-
tients were tested. Data are given as mean ± standard
deviation (SD) of separate experiments. Statistical
significance was assessed for any p value of less than
0.05 using the t-test and Mann–Whitney Rank Sum
Test where appropriate.
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Results
Effective and sustained TGF-β and sox9 combined gene
transfer and overexpression via rAAV in human bone
marrow aspirates
Bone marrow aspirates were first transduced with the
combination rAAV-hTGF-β/rAAV-FLAG-hsox9 to
evaluate the ability of rAAV to mediate direct co-
overexpression of TGF-β and sox9 over time in
aspirates committed toward the chondrogenic differ-
entiation compared with control conditions (rAAV-
lacZ transduction, absence of vector treatment). As
we previously reported that rAAV is capable of
successfully expressing functional TGF-β and SOX9
factors separately in human bone marrow aspirates
(Frisch et al. 2016; Rey-Rico et al. 2015), we did not
include single gene treatments here as additional
controls.
An evaluation of the % of the β-gal+ cells revealed
higher transduction efficiencies in aspirates transduced
with rAAV-lacZ after 21 days compared with the other
conditions (2.7- to 3.7-fold difference at 20 or 40 μl vec-
tor, respectively, p ≤ 0.010) (Table 1) as estimated on im-
munohistochemical sections from aspirates (Fig. 1a).
Strong, significant TGF-β expression was also observed
in the aspirates after 21 days especially when rAAV-
hTGF-β was provided to the aspirates as noted by
immunohistochemical analysis that revealed the stron-
gest signal upon concomitant TGF-β and sox9 gene
transfer at the highest vector doses applied (20 μl each
vector) relative to rAAV-lacZ and to untreated aspirates
(Fig. 1a). These results was corroborated by the results
of an TGF-β ELISA (up to 1.9-fold higher amounts of
TGF-β produced when co-applying the TGF-β and sox9
vectors at the highest vector doses versus control condi-
tions, p ≤ 0.050) (Fig. 1b). Strongest sox9 expression was
also observed in aspirates modified by rAAV-FLAG-
hsox9/rAAV-hTGF-β at the highest vector doses while
expression of the FLAG tag was only detected when
applying the sox9 vector (Fig. 1a).
Activation of the proliferative, biosynthetic, and
chondrogenic activities in human bone marrow aspirates
upon co-overexpression of TGF-β and sox9 via rAAV
vectors
We next examined whether rAAV-mediated TGF-β
and sox9 co-overexpression was capable of modulat-
ing the proliferative, metabolic, and differentiation
activities in human bone marrow aspirates main-
tained over time under chondrogenic stimulation
relative to control conditions (rAAV-lacZ, no vector
treatment).
High, significant levels of proliferation were noted
when co-delivering the TGF-β and sox9 vectors to
the aspirates for 21 days especially at the highest
vector doses compared with the other conditions as
noted by histomorphometric evaluations performed
on H&E-stained sections from aspirates (up to 3.2-
fold difference for both the H&E staining intensities
and cell densities, p ≤ 0.010) (Fig. 2a-c), a finding
corroborated when estimating the DNA contents in
the samples (up to 2.7-fold difference, p ≤ 0.010)
(Fig. 2d). Elevated, significant levels of matrix syn-
thesis and chondrogenic differentiation were also
achieved upon TGF-β and sox9 co-gene transfer in
the aspirates after 21 days particularly at the highest
vector doses relative to the other conditions as ob-
served by histomorphometric evaluations performed
on histological sections from aspirates stained for
toluidine blue and type-II collagen (up to 7.5- and
3.8-fold difference for the toluidine blue staining in-
tensities and for those of type-II collagen immuno-
staining, respectively, p ≤ 0.010) (Fig. 3a-c), a finding
supported by the results of an estimation of the
proteoglycan contents in the samples (up to 2.5-fold
difference, p ≤ 0.010) (Fig. 3d). Overall, these find-
ings were corroborated by the results of a real-time
RT-PCR analysis revealing enhanced levels of chon-
drogenic SOX9, ACAN, and COL2A1 expression
upon concomitant TGF-β and sox9 gene delivery in
the aspirates after 21 days particularly when provid-
ing vectors at the highest vector doses compared
with the other conditions (up to 8.9-, 30-, and 2.6-
fold difference for SOX9, ACAN, and COL2A1,
respectively, p ≤ 0.010) (see Fig. 5).
Effects of rAAV-mediated TGF-β and sox9 co-
overexpression on the hypertrophic and terminal differ-
entiation processes in human bone marrow aspirates
We finally evaluated the potential effects of TGF-β
and sox9 co-overexpression via rAAV on the occur-
rence of hypertrophic events in chondrogenically in-
duced human bone marrow aspirates over time
compared with control conditions (rAAV-lacZ, no
vector treatment).
Table 1 Evaluation of the % of β-gal+ cells in rAAV-transduced
human bone marrow aspirates (day 21)
Condition % of β-gal+ cells
no vector 21.6 (0.8)
lacZ (20 μl) 54.5 (2.8)a,b
lacZ (40 μl) 75.1 (1.9)a,b
TGF-β + sox9 (10 μl + 10 μl) 20.9 (1.8)
TGF-β + sox9 (20 μl + 20 μl) 20.3 (2.1)
Data are given as mean (SD). Statistically significant compared with a(TGF-β +
sox9) and b(no vector) conditions (p ≤ 0.010)
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Remarkably, co-application of rAAV-hTGF-β/rAAV-
FLAG-hsox9 at the highest vector doses reduced the levels
of hypertrophy and terminal differentiation in the aspirates
after 21 days compared with the other conditions as noted
by histomorphometric evaluations performed on histological
sections from aspirates stained with alizarin red, type-I, and
-X collagen (up to 1.5-, 1.2-, and 1.3-fold difference for the
alizarin red staining intensities and for those of type-I and
-X collagen immunostaining, respectively, p ≤ 0.010)
(Fig. 4a-d). These results were again supported by findings
of a real-time RT-PCR analysis, showing lower levels of
COL1A1 and COL10A1 expression using TGF-β and sox9
at the highest vector doses after 21 days relative to the other
conditions (up to 15- and 11.2-fold difference for COL1A1
and COL10A1, respectively, p ≤ 0.050) (Fig. 5).
Discussion
As a novel, single-step approach to treat articular
cartilage lesions, direct transplantation of bone
marrow concentrates has the advantage of eliminat-
ing the complex and invasive preparation and ex-
pansion of progenitor cells to treat articular
cartilage lesions (Johnstone et al. 2013; Orth et al.
2014). Yet, while already used in the clinics, such a
procedure has not allowed to reproduce a functional
hyaline cartilage in patients and instead the repair
tissue formed in treated lesions remains of low
quality (Gigante et al. 2012; Kim et al. 2014;
Slynarski et al. 2006). Chondrogenic modification of
such aspirates especially using the clinically adapted
rAAV gene transfer vectors prior to re-implantation
in the site of injury might be a potent tool to im-
prove the processes of cartilage repair (Frisch et al.
2015). Here, we evaluated the potential benefits of
concomitantly overexpressing the chondrogenic
TGF-β and sox9 factors using multiple rAAV vectors
in human bone marrow aspirates with respect to
their stimulatory effects as independent treatments
Fig. 1 Detection of transgene expression in human bone marrow aspirates via rAAV-mediated gene transfer. Aspirates were co-transduced
with rAAV-hTGF-β/rAAV-FLAG-hsox9 (10 or 20 μl each vector), transduced with rAAV-lacZ (20 or 40 μl), or let untreated for over time
(21 days) maintenance in chondrogenic medium as described in the Materials and Methods. The samples were processed after 21 days
to detect (a) the expression of β-gal, TGF-β, SOX9, and the FLAG tag by immunohistochemistry (original magnification x20, bar = 100 μm,
insets at x40, all representative data) and (b) the production of TGF-β by ELISA as described in the Materials and Methods. *,**Statistically
significant compared with control groups (rAAV-lacZ, no vector condition) (*p ≤ 0.050, **p ≤ 0.010)
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in similar samples (Frisch et al. 2016; Rey-Rico et
al. 2015) or as a combination in isolated human
MSCs (Tao et al. 2016).
Our results first indicate that co-overexpression of
TGF-β and sox9 via rAAV can be successfully
achieved at very high levels (~75% transduction effi-
ciencies) in the aspirates over prolonged periods of
time (at least 21 days), in good agreement with our
previous observations in such samples (Rey-Rico et al.
2015). For comparison, other groups demonstrated
the possibility of transducing rabbit and sheep aspi-
rates with more immunogenic adenoviral vectors but
with much higher vector doses (1010 adenoviral parti-
cles per 250 μl of aspirate versus 8 × 105 rAAV parti-
cles per 100 μl here, i.e. a 5 × 103-fold difference)
(Ivkovic et al. 2010; Pascher et al. 2004). Of further
note, combined TGF-β/sox9 gene transfer (especially
at the highest vector doses employed) allowed for the
sustained expression of SOX9 as previously noted
with single rAAV-FLAG-hsox9 transduction (Rey-Rico
et al. 2015) and to a durable production of TGF-β
relative to the control conditions, in the range of
those achieved when providing rAAV-hTGF-β alone
(Frisch et al. 2016). While early on, all types of cells
forming the aspirates (MSCs, hematopoietic cells,
fibroblast-like cells) might be permissive to genetic
modification, over time mostly MSCs may promote
rAAV-mediated overexpression of the transgenes
when continuously maintained under MSC-specific
chondrogenic culture conditions (Frisch et al. 2016).
The present data further show that prolonged,
effective co-overexpression of TGF-β and sox9 led to
increased levels of cell proliferation, matrix biosyn-
thesis, and chondrogenic differentiation in the
Fig. 2 Proliferative activities in human bone marrow aspirates co-transduced with rAAV-hTGF-β/rAAV-FLAG-hsox9. Aspirates were treated and
maintained in culture as described in Fig. 1. The samples were processed after 21 days to monitor the levels of cell proliferation by (a) H&E
staining (original magnification x20, bar = 100 μm, insets at x40, all representative data) with histomorphometric analyses of the intensities of
H&E staining (b) and of the cell densities (c), and (d) by estimating the DNA contents in the aspirates as described in the Materials and Methods.
*,**Statistically significant compared with control groups (rAAV-lacZ, no vector condition) (*p≤ 0.050, **p≤ 0.010)
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aspirates over time (at least 21 days), concordant with
the properties of these factors (Babister et al. 2008; Bi
et al. 1999; Cucchiarini et al. 2009; Frisch et al. 2014;
Ikeda et al. 2004; Johnstone et al. 1998; Kim and Im
2011; Lee et al. 2011; Pagnotto et al. 2007; Steinert et
al. 2009; Tao et al. 2016; Venkatesan et al. 2012) and
with our previous work using independent gene trans-
fer in similar samples (Frisch et al. 2016; Rey-Rico et
al. 2015), and with effects in the range of those
achieved when co-delivering these factors to isolated
human MSCs (Tao et al. 2016). Again, such effects
over time might be attributed to modified MSCs
under continuous chondrogenic stimulation, while
early on, other potentially transduced cell types may
be active via paracrine effects (Frisch et al. 2016).
Equally important, combined TGF-β/sox9 transduction
advantageously delayed premature hypertrophic differ-
entiation in the aspirates versus control treatments,
probably due to the effective, sustained overexpression
of SOX9, a well-known anti-hypertrophic factor
(Rey-Rico et al. 2015; Venkatesan et al. 2012) that
may counterbalance possible hypertrophic effects of
TGF-β (Barry et al. 2001; Frisch et al. 2014; Yoo et
al. 1998).
Overall, we provide notable evidence of the poten-
tial of multiple gene-based approaches as a means
to stimulate the chondroreparative activities in hu-
man bone marrow aspirates in order to generate
practical, direct systems for implantation in sites of
articular cartilage injury. Work is ongoing using
Fig. 3 Biosynthetic activities and chondrogenic differentiation processes in human bone marrow aspirates co-transduced with rAAV-hTGF-β
/rAAV-FLAG-hsox9. Aspirates were treated and maintained in culture as described in Figs. 1 and 2. The samples were processed after 21 days to
evaluate the production of (a) matrix proteoglycans (toluidine blue staining) and type-II collagen (immunostaining) (original magnification x20,
bar = 100 μm, insets at x40, all representative data) with histomorphometric analyses of the intensities of toluidine blue staining (b) and of type-II
collagen immunostaining (c), and (d) by estimating the proteoglycan contents in the aspirates as described in the Materials and Methods. *,**
Statistically significant compared with control groups (rAAV-lacZ, no vector condition) (*p≤ 0.050, **p≤ 0.010)
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samples from animal species (minipigs, sheep) in
order to adapt the current strategy for administra-
tion in clinically relevant, orthotopic models of focal
cartilage defects that provide the natural biochem-
ical and biomechanical microenvironment for chon-
drogenesis (Cucchiarini et al. 2005; Ivkovic et al.
2010; Pascher et al. 2004). Such work may confirm
the therapeutic activities of dual TGF-β/sox9 gene
transfer via rAAV and the advantageous delay in
hypertrophic differentiation in vivo as mediated here
by SOX9 in vitro (as discrepancies may occur in
vivo) to counteract possible deleterious effects of
TGF-β occurring upon direct gene transfer (osteo-
phyte formation, fibrogenesis) (Bakker et al. 2001;
Mi et al. 2003).
Conclusion
The present study describes novel, convenient strat-
egies via rAAV-mediated multiple gene transfer to
modulate the chondrogenic differentiation processes
in human bone marrow concentrates for the
treatment of damaged articular cartilage. Gene trans-
duction efficiencies, cell proliferation, matrix biosyn-
thesis, and chondrogenic differentiation activities
were systemically analyzed and compared over time
in aspirates among all distinct subgroups, revealing
that co-overexpression of TGF-β with SOX9 via
rAAV effectively and durably enhanced such key
chondroregenerative activities. Evaluation in relevant,
preclinical models is ongoing, requesting to exten-
sively translate the current procedure in animal
Fig. 4 Hypertrophic and terminal differentiation processes in human bone marrow aspirates co-transduced with rAAV-hTGF-β/rAAV-FLAG-hsox9.
Aspirates were treated and maintained in culture as described in Figs. 1, 2 and 3. The samples were processed after 21 days to evaluate (a) matrix
mineralization (alizarin red staining) and the production of type-I and -X collagen (immunostaining) (original magnification x20, bar = 100 μm,
insets at x40, all representative data) with histomorphometric analyses of the intensities of alizarin red staining (b) and of type-I collagen (c) and
type-X collagen immunostaining (d) as described in the Materials and Methods. *,**Statistically significant compared with the control groups
(rAAV-lacZ, no vector condition) (*p≤ 0.050, **p≤ 0.010)
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samples, in order to determine the benefits (and
monitor potential hurdles) of the approach in vivo
prior to safe translation in the clinics. Additional
work in human samples will be also further needed
taking into account the impact of age, gender, and
patient pathology on the bone marrow aspirate
responses to the current treatment.
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